AMY A HALE

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner HAYS, KS NPI 1104053560

General Payments — all program years on this page

$672.21

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 44
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $297.39 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $297.3920

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Lilly USA, LLC $136.6011
ABBVIE INC. $50.493
Acerta Pharma LLC $46.393
Amgen Inc. $21.791
Novo Nordisk AS $21.221
Otsuka America Pharmaceutical, Inc. $20.901

By program year

Program yearAmountRecords
2021 $138.129
2022 $44.913
2023 $191.7912
2024 $297.3920

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1100640688 Novo Nordisk Inc $21.22 08/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104604034 AstraZeneca Pharmaceuticals LP $16.13 05/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104704589 AstraZeneca Pharmaceuticals LP $13.34 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105341267 AstraZeneca Pharmaceuticals LP $16.92 04/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107273712 ABBVIE INC. $15.57 02/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107273714 ABBVIE INC. $17.19 03/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107273716 ABBVIE INC. $17.73 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115694744 Amgen Inc. $21.79 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1119086866 Otsuka America Pharmaceutical, Inc. $20.90 05/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135446671 Lilly USA, LLC $18.14 01/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135494698 Lilly USA, LLC $7.61 03/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135506018 Lilly USA, LLC $10.47 05/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135506020 Lilly USA, LLC $7.65 06/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135509596 Lilly USA, LLC $3.62 02/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135509598 Lilly USA, LLC $17.48 03/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135521539 Lilly USA, LLC $6.74 04/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135521541 Lilly USA, LLC $7.50 06/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135530841 Lilly USA, LLC $18.84 02/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135530845 Lilly USA, LLC $16.96 08/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135530849 Lilly USA, LLC $21.59 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.